Predictors of Post-Thrombectomy Cognitive Impairment in Acute Ischemic Stroke Patients
ConditionIschemic Stroke, Acute
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssiut University
About this trial
This prospective cohort study investigates predictors of post-stroke cognitive impairment (PSCI) in patients undergoing endovascular thrombectomy (EVT) for acute ischemic stroke due to large vessel occlusion. Adult patients with successful reperfusion (mTICI 2b-3) will be followed at 3 and 6 months to assess cognition, functional recovery, and depression. Predictors across clinical, procedural, radiological, and laboratory domains will be analyzed. The study aims to identify risk factors for PSCI, estimate its prevalence, and evaluate its impact on outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults (≥18 years).
Acute ischemic stroke due to anterior circulation LVO confirmed by imaging undergoing EVT per guidelines.
Successful reperfusion (mTICI 2b-3)
Able to provide consent.
Disqualifiers
Severe aphasia/coma interfering with cognitive assessment.
Pre-existing dementia ( using Arabic version of the Short Form of the Informant Questionnaire on Cognitive Decline in the Elderly).
Non-ischemic etiology.
Death within 72 hours.
Trial population
As described in inclusion/exclusion criteria
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
120 Participants
are grouped into 1 trial groupGroup A: Postthrombectomy
Trial outcomes
Primary outcomes
1
Cognitive impairment after thrombectomy (MoCA)
Cognitive status will be assessed using the Arabic version of the Montreal Cognitive Assessment (MoCA, score range 0-30, with scores \<26 indicating impairment). The primary outcome will be the prevalence of post-stroke cognitive impairment (PSCI) among thrombectomy patients.
Time frame
3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomySecondary outcomes
1
Domain-specific cognitive performance (OCS)
For participants scoring \<26 on MoCA, the Oxford Cognitive Screen (OCS) will be administered to evaluate specific domains of cognition (attention, executive function, memory, language, visuospatial ability).
Time frame
3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy2
Depression and anxiety symptoms (HADS)
Psychological status will be measured using the Hospital Anxiety and Depression Scale (HADS, score range 0-21 per subscale). Outcomes will include mean scores and prevalence of clinically significant symptoms.
Time frame
3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy3
Functional independence (Barthel Index)
Functional status will be assessed using the Barthel Index (score range 0-100). Higher scores indicate greater independence in activities of daily living.
Time frame
3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy4
Global disability (modified Rankin Scale)
Global disability will be measured using the modified Rankin Scale (mRS, score range 0-6, with 0 indicating no symptoms and 6 indicating death).
Time frame
3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomyLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: